Inpharma 1611 - 27 Oct 2007

SR indapamide most effectiveantihypertensive in meta-analysisSustained-release (SR) indapamide appears to be the

most effective agent for producing significant reductionsin BP within 8–12 weeks in patients with hypertension,according to the findings of a meta-analysis by Frenchinvestigators.

The analysis included 80 randomised, double-blind,controlled trials involving 10 818 patients who receivedmonotherapy with one of 16 antihypertensive agents* atvarying dosages.

The average weighted reductions in systolic BP (SBP)over 8–12 weeks were most marked with diuretics, andin particular SR indapamide 1.5 mg/day (mean changefrom baseline –22.2mm Hg). Indapamide reduced SBP,at any dosage, to a greater extent than any of the otheragents. Weighted average reductions in diastolic BPwere generally similar for all of the 16 antihypertensives.

The authors say that this new analysis supports theresults of earlier investigation, in that SR indapamideappears to be the most effective drug for producingsignificant reductions in BP within 2–3 months.* including diuretics, a β-blocker, calcium channel antagonists, ACEinhibitors, angiotensin receptor blockers and a renin inhibitor.

Baguet JP, et al. Updated meta-analytical approach to the efficacy ofantihypertensive drugs in reducing blood pressure. Clinical Drug Investigation 27:735-753, No. 11, 2007 801055562

1

Inpharma 27 Oct 2007 No. 16111173-8324/10/1611-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved